Browsing Category
Pharma Industry News
4722 posts
Business-News-Today.com section for global pharma industry news, Indian pharma sector latest news, pharma sector news today, pharmaceuticals industry news.
How GTx-104 may improve ICU dosing consistency in subarachnoid hemorrhage
How Grace Therapeutics’ GTx-104 could improve ICU dosing consistency and reshape hospital economics in subarachnoid hemorrhage care. Read the full BNT analysis.
Is elraglusib emerging as a new frontline option in metastatic PDAC?
Read how Actuate Therapeutics’ elraglusib Phase 2 survival data could reshape metastatic PDAC treatment and investor expectations.
How HB2198’s Phase 1 launch could reshape the lupus immune-reset therapy race
How HB2198’s Phase 1 launch could reshape the lupus immune-reset therapy race and what it means for biotech strategy, competition, and valuation. Read more.
How CLR 125 may test the limits of precision radiopharmaceutical therapy in solid tumors
Could CLR 125 redefine precision radiopharmaceutical therapy in solid tumors? Read what this means for Cellectar Biosciences, Inc. and oncology markets.
AACR Annual Meeting 2026: what cancer researchers and pharma professionals need to know before San Diego
AACR Annual Meeting 2026 runs April 17-22 at San Diego Convention Center. Over 7,400 abstracts, six plenaries, AI, CAR T, ADCs and RAS inhibitor data.
How rare disease medicine access in Africa is moving from ad hoc supply to structured compliance-led programs
How Veld Pharmaceuticals and Chiesi are reshaping rare disease drug access in Africa through compliance-led programs. Read what this means for the sector.
Could essential tremor finally be entering a new treatment era after Praxis’ Phase 3 results?
Praxis Precision Medicines’ Phase 3 results could reshape essential tremor treatment and re-rate the neurology market. Read what this means for investors.
Could PP2A-targeted immunotherapy combinations improve outcomes in ovarian clear cell carcinoma?
Could PP2A-targeted immunotherapy reshape ovarian cancer treatment and Lixte’s valuation story? Read the executive analysis on what changes next.
What this Phase 1 milestone reveals about the next wave of GPCR-driven endocrine therapeutics
What does Septerna’s Phase 1 milestone mean for GPCR-driven endocrine innovation? Read how SEP-479 could reshape biotech strategy and market sentiment.
Immutep (ASX: IMM) surges 48% on FDA orphan drug designation: Is the STS pivot the new thesis?
Immutep (ASX: IMM) jumped 48% after the FDA granted orphan drug status for eftilagimod alfa in soft tissue sarcoma. Here is what the EFTISARC-NEO data means for the investment case.